ロード中...
Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases
BACKGROUND: High-dose intravenous immune globulins (IVIg) are frequently used in refractory juvenile dermatomyositis (JDM) but are often poorly tolerated. High-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins (fSCIg) allow the administration of much higher doses of immu...
保存先:
| 出版年: | Pediatr Rheumatol Online J |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5022227/ https://ncbi.nlm.nih.gov/pubmed/27623619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12969-016-0112-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|